Amgen Inc. $AMGN Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 35.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 72,161 shares of the medical research company’s stock after selling 39,403 shares during the period. Los Angeles Capital Management LLC’s holdings in Amgen were worth $23,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Norges Bank acquired a new stake in shares of Amgen during the 4th quarter worth approximately $2,164,162,000. Capital World Investors grew its stake in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Geode Capital Management LLC grew its stake in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Vanguard Group Inc. grew its stake in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after acquiring an additional 961,975 shares during the period. Finally, National Bank of Canada FI grew its stake in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after acquiring an additional 863,216 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Performance

Shares of AMGN opened at $349.58 on Monday. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm’s fifty day moving average is $341.35 and its two-hundred day moving average is $345.49. The stock has a market cap of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.51 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on AMGN shares. Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Wells Fargo & Company lifted their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $353.81.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.